RICHMOND, VA — Bright Path Pharmaceuticals, LLC (privately held), today announced that ChemWerth’s Chief Scientific Officer, Dr. Xiping Su, has joined the Board of the company following their investment in BPP. Xiping Su, Ph.D., is an organic chemistry and ChemWerth’s head of product development. ChemWerth has extensive experience in regulatory affairs having gained approval for 220 Drug Master Files (“DMFs”) submission with the FDA. ChemWerth is partnering with BPP to identify API targets, prosecute DMP filings and distribute product.
Mr. Quinones acknowledged, “This is a major development for the company and will are privileged to have this partnership.” Mr. Allen affirmed, “ChemWerth has been a leader in bringing lower cost, high quality medicines into the U.S. and Europe. Dr. Su’s experience is unparalleled in our industry.”
About Bright Path Pharmaceuticals, LLC
Bright Path Pharmaceuticals, LLC is a developmental stage bio-pharmaceutical manufacturing company, dedicated to developing best-in-class continuous-flow manufacturing for the pharmaceutical sector. For more information, please visit www.brightpathrx.com.
About ChemWerth, Inc.
Established in 1982 by Peter Werth, ChemWerth is a full service generic active pharmaceutical ingredient (API) development and supply company providing cGMP quality APIs to regulated markets worldwide. ChemWerth is a global company headquartered in the United States, with offices in China and India.
Through exclusive development and CMO partnerships, ChemWerth provides expertise in new product selection & development; regulatory & compliance support; and secure supply chain logistics. For more information, please visit www.chemwerth.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about Bright Path Pharmaceuticals’ plans, objectives, expectations and intentions with respect to cash flow requirements, future operations and products, and development activities, and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Bright Path Pharmaceuticals’ actual results to be materially different than those expressed in or implied by Bright Path Pharmaceuticals’ forward-looking statements. For Bright Path Pharmaceuticals, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success and design of manufacturing facilities; and Bright Path Pharmaceuticals’ need for and ability to obtain additional financing. Bright Path Pharmaceuticals undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.